S-x-c Containing (e.g., Sulfates, Etc.) (x Is Chalcogen) Patents (Class 514/517)
-
Publication number: 20100266516Abstract: An aqueous shear-thinning personal care composition comprises: (a) at least 3 wt % of a sulfonate compound of general formula (I): where R1 represents a C8-22 alkyl group alkyl group; R2 represents a C1-4 alkyl group; each of R3, R4 and R5 independently represents a hydrogen atom or a C1-4 alkyl group; and M+ represents a sodium or potassium cation; (b) at least 3 wt % of an amphoteric or zwitterionic surfactant; (c) at least 10 wt % of water; and (d) at least 0.5 wt % of an additional component in the form of particles or droplets suspended in the composition. The composition is stable in an aqueous environment and can be formulated with a wide range of additional components.Type: ApplicationFiled: November 17, 2008Publication date: October 21, 2010Applicant: Innospec LimitedInventor: Philip Cotrell
-
Publication number: 20100267690Abstract: Guanidine derivatives having a condensed tricyclic ring of formula 1: are disclosed, wherein U is C(O), CRaRb, O, NRa or S(O)m; V is CRaRb or NRa; W is S(O)m; wherein Ra is H, alkyl, cycloalkyl, alkenyl or aralkyl; Rb is H, alkyl, OH, ORa or OCORa, and m is the integer 0, 1 or 2; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein with the proviso that at least one of R1, R2, R3, R4, R5, R6, R7 or R8 is guanidino or guanidino carbonyl. These derivatives are sodium-proton exchange inhibitors and are useful as medicaments for the treatment of, for example, organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy, hypertension, cell proliferative disorders and diabetes.Type: ApplicationFiled: June 30, 2010Publication date: October 21, 2010Applicant: Piramal Life Sciences LimitedInventors: Bansi LAL, Swati Bal-Tembe, Usha Ghosh, Arun Kumar Jain, Tulsidas More, Anil Ghate, Jacqueline Trivedi, Sapna Parikh
-
Publication number: 20100255004Abstract: The invention provides novel methods for designing and administering therapeutic treatments for subjects afflicted with cancer. One aspect provides methods of identifying RTK pathways in a cancer and formulating treatment plans based on a plurality of RTK inhibitors. The invention further provides methods for evaluating candidate tyrosine kinase inhibitors for therapeutic efficacy.Type: ApplicationFiled: April 11, 2008Publication date: October 7, 2010Applicant: Dana Farber Cancer InstituteInventors: Ronald A. DePinho, Jayne M. Stommel
-
Publication number: 20100249225Abstract: Pharmaceutical formulations of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine and the metabolites thereof for treating anxiety, anxiety attacks and disorders as well as depression. Related methods of treating anxiety and anxiety attacks or depression are also provided, including methods of administering the active compounds as adjuvants to an antidepressant.Type: ApplicationFiled: June 9, 2010Publication date: September 30, 2010Applicant: GRUENENTHAL GmbHInventors: Petra Bloms-Funke, Werner Englberger, Hagen-Heinrich Hennies
-
Publication number: 20100247528Abstract: The invention provides an array comprising a substrate and a set of addressable elements, wherein each addressable element comprises (i) a polynucleotide that specifically binds to a target molecule, (ii) a polypeptide that specifically binds to target molecule, or (iii) a combination of (i) and (ii), wherein the target molecule is selected from the group of cancer-related target molecules as defined herein. Related kits, methods, and uses as described herein are further provided by the invention.Type: ApplicationFiled: September 4, 2008Publication date: September 30, 2010Inventors: Kent Hunter, Nigel Crawford
-
Publication number: 20100240616Abstract: Omega-3 lipid compounds of the general formula (I): wherein R1 and R2 are the same or different and are chosen from a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, a carboxy group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; P represents a hydrogen atom, (Formula II) wherein P2, P3, and P4 are chosen from a hydrogen atom, an alkyl group, and a C14-C22 alkenyl group, wherein the alkyl and alkenyl groups are optionally substituted with a hydroxy group, (Formula III), (Formula IV), or (Formula V); and Y is a C14-C22 alkenyl group with at least one double bond, having E and/or Z configuration; or any pharmaceutically acceptable complex, solvate, salt or pro-drug thereof, with the proviso that R1 and R2 are not simultaneously a hydrogen atom.Type: ApplicationFiled: November 1, 2007Publication date: September 23, 2010Inventors: Anne Kristin Holmeide, Jenny Rosman
-
Publication number: 20100240747Abstract: Disclosed herein are motuporamine mimic agents and methods of making and using same. Particularly exemplified are motuporamine mimic agents comprising cytotoxic activity and/or anti-metaplastic activity.Type: ApplicationFiled: June 1, 2010Publication date: September 23, 2010Inventor: Otto Phanstiel
-
Patent number: 7799762Abstract: The present invention is directed in particular to dipeptide-like compounds derived from functionally substituted amino acids, having fatty acid chains bound thereto through amidification of the amine functional groups of said dipeptide-like compounds, one end portion of which bears an accessory functional side chain spacer, with the other end portion being an acid group either in neutral or charged state. Compounds of the present invention have immunomodulating properties like adjuvants, In addition, compounds of the invention can be grafted on a given antigen in order to modulate or tune the immune response or can be equally grafted on a pharmaceutical carrier to enhance the therapeutic effect or targeting thereof. Accordingly, compounds of the invention find use in human and veterinary medicine both as immunogens and diagnostic tools.Type: GrantFiled: December 21, 2000Date of Patent: September 21, 2010Assignee: OM PharmaInventors: Jacques Bauer, Olivier Richard Martin, Sylvain Rodriguez
-
Publication number: 20100234379Abstract: The endocannabinoid transporter and FAAH are sites of modulation that allow pharmacological enhancement of protective endocannabinergic signals. Selective inhibitors of the transporter and inhibitors of FAAH caused additive augmentation of endogenous signaling events mediated by the cannabinoid CB1 receptor. Disruption of such signals has been shown to prevent neuronal maintenance processes and increase vulnerability to brain damage. Here, blocking endocannabinoid inactivation enhanced cannabinergic activity and ameliorated cellular disturbances associated with excitotoxicity. Modulating the endocannabinoid system in this way also prevented excitotoxic behavioral abnormalities including memory impairment. Collectively, these results indicate that increasing endocannabinoid responses by inhibiting the endocannabinoid transported and/or the inhibiting FAAH leads to molecular, cellular, and functional protection against excitotoxic insults like stroke and traumatic brain injury.Type: ApplicationFiled: July 28, 2006Publication date: September 16, 2010Inventors: Ben A. Bahr, Alexandros Makriyannis, David A. Karanian
-
Publication number: 20100227010Abstract: A pest-combating composition including sodium lauryl sulfate and one or more of C6-12 fatty acids, preferably lauric and/or capric and/or caprylic acid, soy methyl ester, and 2-undecanone, and methods of combating pests utilizing same, are disclosed. The compositions can include a carrier oil such as silicon oil, soy methyl ester, or a vegetable oil, and can be in the form of an emulsion. The composition may be constituted as a spray composition, an aerosol, a lotion, a paste, or another compositional form. Pests that may be usefully combated with such composition include flying insects, including flies, mosquitoes, and wasps, ants, including arthropods such as fire ants, ticks, fleas, cockroaches, silver fish, thrips, gnats, aphids, Japanese beetles, and agricultural and horticultural arthropods and insects including beetles (potato and bean), flea beetles, fleahoppers, squash bugs, slugs, leaf hoppers, harlequin bugs, milk weed bugs, spiders, mites, lice, rodents, and deer.Type: ApplicationFiled: February 2, 2010Publication date: September 9, 2010Applicant: ECOBLEND, LLCInventor: Allen Jones
-
Publication number: 20100227791Abstract: Disclosed is the use of compounds of formula (I) wherein X, Y and Z are as defined in the description of the invention, for the preparation of an antitumor medicament, optionally in combination with different biologically active substances.Type: ApplicationFiled: January 7, 2010Publication date: September 9, 2010Inventors: Gianfranco Peluso, Menotti Calvani
-
Publication number: 20100216859Abstract: Novel curcumin-analog compounds are disclosed that are antioxidants useful in inhibition of pro-inflammation, angiogenic, and vascular permeability factors and elimination of reactive oxygen species. The curcumin compounds specifically inhibit VEGF and are useful in treating various diseases that are mediated through the oxidative stress pathway, including those that are characterized by inflammation, angiogenesis, or vascular leakage.Type: ApplicationFiled: October 14, 2009Publication date: August 26, 2010Inventor: Danyang Chen
-
Publication number: 20100209354Abstract: The invention relates to nanoparticles made from organometallic hybrid materials made from iron carboxylates, used for example as contrast agents. The particles can also be used for the encapsulation and vectoring of molecules of interest such as active3 pharmaceutical agents, cosmetically interesting compounds and markers. Apart from the intrinsic properties thereof for imaging, said nanoparticles give good results in terms of capacity for loading with medicaments and in biocompatibility.Type: ApplicationFiled: October 1, 2008Publication date: August 19, 2010Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS, UNIVERSITE DE VERSAILLES - SAINT-QUENTIN- EN-YVELINESInventors: Patricia Horcajada-Cortes, Gérard Ferey, Christian Serre, Ruxandra Gref, Patrick Couvreur
-
Publication number: 20100203110Abstract: The present invention relates to methods of treating a cancerous tumor in a subject comprising administering to the subject an effective amount of 3-bromopyruvate. The 3-bromopyruvate may be administered intraarterially directly to a tumor as a continuous intraarterial infusion. The present invention also relates to methods for identifying agents that inhibit type II hexokinase activity.Type: ApplicationFiled: December 17, 2007Publication date: August 12, 2010Applicant: The Johns Hopkins UniversityInventors: Jean-Francois Geschwind, Mustafa Vali
-
Publication number: 20100189683Abstract: This invention relates to pulsatile dose administration of gossypol or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.Type: ApplicationFiled: December 10, 2009Publication date: July 29, 2010Applicant: Ascenta Therapeutics, Inc.Inventors: Jon T. Holmlund, Mel Sorensen, Lance Leopold, Dajun Yang
-
Patent number: 7745488Abstract: A composition and method for promoting neutrophil survival and activation such as the treatment of neutropenia arising as an undesirable side effect of chemotherapy and radiation therapy. A composition containing medium-chain fatty acids, such as Capri acid or caprylic acid, or salts or triglycerides thereof, or mono- or diglycerides or other analogues thereof or medium-chain triglycerides (MCT) is administered to a human or animal needing treatment in an amount sufficient to reduce or eliminate neutropenia. The composition is administered in an amount effective to treat the disorder. The methods are also useful in the management of bone narrow transplantation and in the treatment of various neutropenic diseases.Type: GrantFiled: April 18, 2002Date of Patent: June 29, 2010Assignee: Prometic Biosciences, Inc.Inventors: Lyne Gagnon, Jean Barabe, Pierre Laurin, Christopher Penney, Boulos Zacharie
-
Publication number: 20100093601Abstract: Pathogenic effector proteins which include one or more RxLR, dEER, Pexel or analogous motifs are blocked from entry into plant or animal cells by binding one or more of the motifs with a blocking compound which prevents binding of phosphoinositides or other polar lipids to the motifs which is a prerequisite for translocation of the pathogenic effector proteins into the plant or animal cell. The blocking compounds can take a variety of forms including synthetic peptides or the hydrophilic head-groups of phosphoinositides, phosphatidic acids, phospholipids, or sphingolipids. Suitable blocking compounds can be identified by assays demonstrating binding to RxLR, dEER, Pexel or analogous motifs. In addition, pathogenic effector proteins can be identified by analyzing whether they contain structural RxLR motifs using hidden markov modeling.Type: ApplicationFiled: May 19, 2009Publication date: April 15, 2010Inventors: Brett Tyler, Daolong Dou, Shiv Kale, Biao Gu
-
Publication number: 20100080756Abstract: CXCR3 agonists, including natural CXCR3 ligands, promote bone marrow regeneration, increase peripheral white blood cells, and increase survival if administered prior to treatment of a subject with chemotherapy or radiotherapy. Similar effects are obtained by administering an CXCR3 antagonists following chemotherapy radiotherapy. Compositions and methods are presented for the treatment of cancer and bone marrow diseases.Type: ApplicationFiled: September 23, 2009Publication date: April 1, 2010Inventors: Wei Han, Huili Lu, Di Xiang
-
Publication number: 20100076037Abstract: Embodiments of the invention relate to the treatment of neuropathic pain in mammals. Embodiments of the invention include methods for treating neuropathic pain as well as methods for preparing medicaments used in the treatment of mammalian pain. Preferably, methods of the invention comprise the use of PPARgamma agonists for the treatment of mammalian pain.Type: ApplicationFiled: November 1, 2007Publication date: March 25, 2010Inventors: Lillian W. Chiang, Tage Honore
-
Publication number: 20100048595Abstract: The invention generally relates to the use of archaea to modulate nutrient harvesting in a subject. In particular, the invention provides methods that use archaea to modulate the nutrient harvesting functions of the microbiota in the subject's gastrointestinal tract.Type: ApplicationFiled: March 22, 2006Publication date: February 25, 2010Applicant: WASHINGTON UNIVERSITY IN ST. LOUISInventors: Jeffrey I. Gordon, Sparrow Buck Samuel
-
Publication number: 20100035984Abstract: The invention relates to the use of an antibacterial compound, which is derived from alliaceae, as a natural additive in animal feed, intended as an antimicrobial agent in animal feed, and as an alternative, due to its antibacterial nature, to the use of antibiotics as growth promoters, proposing the use of the compound separately (purity greater than 95%), and encapsulated or supported on different inert materials or food coatings, and in that said compound preferably consists of propyl propylthiosulfinate and, in an alternative variant, of propyl propylthiosulfonate.Type: ApplicationFiled: September 24, 2007Publication date: February 11, 2010Applicant: DMC Research Center, S.L.Inventors: Pilar Garcia Pareja, Armando Lara Cambil, Luis A. Rubio Sanmillan, Eduarda Molina` Alcaide
-
Publication number: 20100015079Abstract: The present invention relates to a cosmetic composition which comprises a compound of the formula R2R3N—(CH2)n—SO2R1, in which R1 is OR4 or NR5R6; R2 and R3, independently of one another, are H, C1-C6-alkyl, phenyl-C1-C4-alkyl, HCO or C1-C4-alkyl-CO; R4 is C1-C6-alkyl; R5 and R6, independently of one another, are H or C1-C6-alkyl; and n is 2, 3 or 4. The cosmetic compositions can be used for protecting the hair and the skin against oxidative damage and for regenerating oxidatively damaged hair or oxidatively damaged skin.Type: ApplicationFiled: April 19, 2007Publication date: January 21, 2010Inventor: Karl-Heinz Schrader
-
Publication number: 20090312274Abstract: Estrogenic compositions comprising nyasol and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.Type: ApplicationFiled: June 12, 2009Publication date: December 17, 2009Applicant: Bionovo, Inc.Inventor: Isaac Cohen
-
Patent number: 7632863Abstract: This invention relates to a compound of formula (I), 3,4,5,4?-tetramethoxyl-?,?-diphenylethane-3?-O-sodium sulphate, and its use in the preparation of antineoplastic pharmaceutical.Type: GrantFiled: January 31, 2008Date of Patent: December 15, 2009Assignee: The Jian Cell Biomedical Research Co., Ltd.Inventors: Yiping Li, Ning Li, Danping Zhou, Lizuan Chen
-
Publication number: 20090203740Abstract: 4-(trifluoromethanesulfonyloxyphenyl)propionic acid derivatives and pharmaceutical composition containing such compounds are useful in inhibiting the chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, these metabolites are devoid of cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.Type: ApplicationFiled: March 21, 2005Publication date: August 13, 2009Applicant: Dompe' pha.r.ma S.p.AInventors: Marcello Allegretti, Maria Candida Cesta, Riccardo Bertini, Marco Mosca, Francesco Colotta
-
Publication number: 20090191129Abstract: This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).Type: ApplicationFiled: October 23, 2008Publication date: July 30, 2009Inventors: Lutz LEHMANN, Andrea Thiele, Tobias Heinrich, Thomas Brumby, Christer Halldin, Balazs Gulyas, Sangram Nag
-
Publication number: 20090192220Abstract: A method for treating a solid tumor in a subject comprises administering to the subject an ACAT inhibitory compound or a prodrug thereof, for example avasimibe, wherein (a) the solid tumor is at least about 2 mm in diameter and (b) the compound or prodrug thereof is administered in an amount that is therapeutically effective, but ineffective to cause unacceptable toxicity to normoxic tissues.Type: ApplicationFiled: November 17, 2008Publication date: July 30, 2009Applicant: Ore Pharmaceuticals Inc.Inventors: David William White, Jin Shengfang, Robert Mark Coopersmith, Scott Edward Malstrom, Thi T. Nguyen
-
Publication number: 20090082441Abstract: The present application describes deuterium-enriched tesaglitazar, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: September 18, 2008Publication date: March 26, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090082440Abstract: Pantoic acid ester neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.Type: ApplicationFiled: September 5, 2008Publication date: March 26, 2009Inventors: Bernd Jandeleit, Yunxiao Li, Mark A. Gallop, Noa Zerangue, Peter A. Virsik, Wolf-Nicolas Fischer
-
Publication number: 20090069419Abstract: Masked carboxylate neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.Type: ApplicationFiled: September 5, 2008Publication date: March 12, 2009Inventors: Bernd Jandeleit, Yunxiao Li, Mark A. Gallop, Noa Zerangue, Peter A. Virsik, Wolf-Nicolas Fischer
-
Patent number: 7498311Abstract: A method for treating migraine in non-epileptic subjects which involves administering to subjects an effective amount of a pharmaceutical composition comprising a sulfamate of the following formula:Type: GrantFiled: January 6, 2006Date of Patent: March 3, 2009Assignee: New England Medical Center Hospitals, Inc.Inventors: Bruce L. Ehrenberg, Anita K. Wagner
-
Patent number: 7479507Abstract: 3,5-di-substituted-4-hydroxybenzylidene phosphonates and sulfonates useful in treating inflammatory disease, particularly osteoarthritis, and elastomeric particles for oral delivery of drugs are disclosed.Type: GrantFiled: January 13, 2004Date of Patent: January 20, 2009Inventors: Adam Heller, Charles Haymore
-
Publication number: 20090004229Abstract: The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane.Type: ApplicationFiled: June 25, 2008Publication date: January 1, 2009Applicant: OSMOTICA COSTA RICA SOCIEDAD ANONIMAInventors: Ana C. Pastini, Joaquina Faour, Juan A. Vergez, Marcelo A. Ricci, Gustavo A. Fischbein
-
Patent number: 7459585Abstract: The present invention provides an AP-1 activation inhibitor, NF-kappa B activation inhibitor, inflammatory cytokine production inhibitor, matrix metalloprotease production inhibitor, inflammatory cell adhesion molecule expression inhibitor, anti-inflammatory agent, antirheumatic agent, immunosuppressant, cancer metastasis inhibitor, remedy for arteriosclerosis and antiviral agent which contain the benzene derivative of the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.Type: GrantFiled: March 24, 2005Date of Patent: December 2, 2008Assignee: Ajinomoto Co., Inc.Inventors: Yukio Iino, Kohichi Fujita, Takashi Tsuji, Ariko Kodaira, Kenji Takehana, Tsuyoshi Kobayashi, Takashi Yamamoto
-
Publication number: 20080234369Abstract: This invention relates to a compound of formula (I), 3,4,5,4?-tetramethoxyl-?,?-diphenylethane-3?-O-sodium sulphate, and its use in the preparation of antineoplastic pharmaceutical.Type: ApplicationFiled: January 31, 2008Publication date: September 25, 2008Applicant: The Jiang Cell Biomedical Research Co., Ltd.Inventors: Yiping Li, Ning Li, Danping Zhou, Lizuan Chen
-
Publication number: 20080207750Abstract: A pharmaceutical composition containing N-chlorotaurine is administered to a mammal to treat oozing tissue deficiencies.Type: ApplicationFiled: December 8, 2003Publication date: August 28, 2008Applicant: Pathogenics LLCInventors: Waldemar Gottardi, Andreas Neher, Markus Nagl
-
Patent number: 7351695Abstract: The invention encompasses novel salts of topiramate, and pharmaceutically acceptable polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, or amorphous forms thereof, as well as pharmaceutical compositions and pharmaceutical unit dosage forms containing the same. In particular, the invention encompasses pharmaceutically acceptable salts of topiramate, including without limitation topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms thereof. The invention further encompasses novel co-crystals or complexes of topiramate, as well as pharmaceutical compositions comprising them. The invention also encompasses methods of treating or preventing a variety of diseases and conditions including, but not limited to, seizures, epileptic conditions, tremors, cerebral function disorders, obesity, neuropathic pain, affective disorders, tobacco cessation, migraines, and cluster headache.Type: GrantFiled: November 19, 2003Date of Patent: April 1, 2008Assignee: Ortho-McNeil Pharmaceuticals, Inc.Inventors: Öm Almarssoo, Jules Remenar, Matthew L. Peterson
-
Patent number: 7351427Abstract: Pharmaceutically acceptable liposome-encapsulated busulphan formulations for parenteral administration are provided, as well as such formulations furthermore comprising glutathione and/or at least one glutathione precursor and a process for manufacture of the preparations. The formulations are stable, have improved biodistribution and significantly reduced side effects over those produced by oral administration or parenteral administration of free drug. The formulations are useful as part of stem cell and/or bone marrow transplant conditioning regimens. A method of treatment of a mammal by use of such formulations.Type: GrantFiled: April 30, 2003Date of Patent: April 1, 2008Assignee: Busulipo ABInventors: Zuzana Hassan, Moustapha Hassan
-
Publication number: 20070219268Abstract: The field of the present invention comprises pharmaceuticals and pharmaceutical treatments, including, for example, (i) compounds and formulations which cause the augmentation of anti-cancer activity (i.e., by enhancement of the lethal cytotoxic action in stimulatory [inducing oxidative stress] and/or depletive [decreasing anti-oxidative capacity] manner) of chemotherapeutic agents, in a selective manner; (ii) methods of administering said anti-cancer augmentation compounds and formulations; (iii) delivery devices containing said anti-cancer augmentation compounds and formulations; and (iv) methods of using said anti-cancer augmentation compounds, formulations, and devices to treat subjects in need thereof.Type: ApplicationFiled: March 16, 2007Publication date: September 20, 2007Inventor: Frederick H. Hausheer
-
Patent number: 7268152Abstract: Compounds of Formula (IA) and Formula (IB) wherein R1, R2, R3, R4, R5, and R6 are as defined herein for Formula (IA) or Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.Type: GrantFiled: March 21, 2003Date of Patent: September 11, 2007Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Younes Bekkali, Mario G. Cardozo, Christian Hanke Justus Joachim Harcken, Thomas M. Kirrane, Daniel Kuzmich, John Robert Proudfoot, Hossein Razavi, Hidenori Takahashi, David S. Thomson, Ji Wang, Renee Zindell
-
Patent number: 7244762Abstract: This invention relates to 2-substituted D-homo-estra-1,3,5(10)-trien-3-yl sulfamates of general formula I (I), in which R3 means a C1-C5-alkyl or C1-C5-alkyloxy group as well as their use for the production of a pharmaceutical agent for treating tumor diseases, which can be influenced positively by the inhibition of tubulin polymerization. The compounds according to the invention are distinguished by a D-homosubstitution.Type: GrantFiled: February 19, 2004Date of Patent: July 17, 2007Assignee: Sterix LimitedInventors: Alexander Hillisch, Olaf Peters, Christian Gege, Gerhard Siemeister, Eberhard Unger, Bernd Menzenbach
-
Patent number: 7235687Abstract: The invention relates to the bis-hydrochloride of 4,4?-dithiobis-(3-aminobutane-1-sodium sulphonate) and the bis-trifluoracetate of 4,4?-dithiobis-(3-aminobutane-1-sulphonate of 2,2-dimethylpropyl). The invention also relates to a pharmaceutical composition comprising one of said compounds and to the use of one of said compounds for the production of a medicament. The invention is suitable for use in a treatment method for hypertension and indirectly- or directly-linked illnesses.Type: GrantFiled: July 16, 2003Date of Patent: June 26, 2007Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Marie-Claude Fournie-Zaluski, Catherine Llorens-Cortes, Bernard Pierre Roques, Pierre Corvol
-
Patent number: 7199081Abstract: An aqueous composition suitable for applying fungicides to plant propagation materials is provided, comprising water and a blend of the following components, by weight: a) 2–10% of a surface-active agent comprising a1) at least one anionic surfactant; b) 0.5–10% of at least one polymer selected from water-dispersible polymers and water-soluble film-forming polymers; c) 4–20% of at least one inorganic solid carrier; and d) 3–20% of at least one antifreeze agent. In one embodiment, the composition comprises a fungicidally effective amount of at least one fungicidally active compound. The inventive composition is storage stable, ready-to-apply (RTA), ecologically and toxicologically favorable and has good fungicidal efficacy.Type: GrantFiled: February 28, 2005Date of Patent: April 3, 2007Assignee: Syngenta Crop Protection, Inc.Inventors: Christian Schlatter, Ravi Ramachandran
-
Patent number: 7183317Abstract: It has been discovered that certain selected ethers of probucol, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL cholesterol. These compounds may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors or (c) increasing the half life of apoAI-HDL.Type: GrantFiled: July 8, 2004Date of Patent: February 27, 2007Assignee: Atherogenics, Inc.Inventors: James A. Sikorski, Jayraz Luchoomun, Charles Q. Meng, Uday Saxena
-
Patent number: 7176192Abstract: This invention relates to a method of treating a patient suffering from ionizing radiation exposure, or of treating a patient about to undergo ionizing radiation therapy. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.Type: GrantFiled: October 26, 2001Date of Patent: February 13, 2007Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Frederick H. Hausheer
-
Patent number: 7173019Abstract: The invention relates to compounds of the following formula (I). In these compounds, R1, R2, R3 and R4 are each independently a substituted or unsubstituted cyclitol with a ring comprising six carbon atoms, or hydrogen, substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, alkyloxycarbonyl, or alkylaminocarbonyl. At least two of R1, R2, R3 and R4 comprise the substituted or unsubstituted cyclitol. The linker can be any one of the following: —(CH2)w—, —(CH2)x—C6H4—(CH2)x—, —(CH2)y—NR5—(CH2)y—, and —(CH2)z—HCR6—(CH2)z—; wherein: w, x, y and z are independently an integer having a value of 0–10; R5 is a substituted or unsubstituted cyclitol with a ring comprising six carbon atoms; and, R6 is —OH, —OSO3Na, —OSO3Na substituted with alkyl, cycloalkyl or aryl, or substituted or unsubstituted alkyl, cycloalkyl or aryl. The compounds can also include substituted or unsubstituted cyclitol carbamides with the linker bond at the carbamide nitrogen.Type: GrantFiled: July 4, 2002Date of Patent: February 6, 2007Assignee: The Australian National UniversityInventors: Martin Gerhardt Banwell, Ligong Liu, Christopher Richard Parish, Craig Geoffrey Freeman
-
Patent number: 7153877Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.Type: GrantFiled: December 9, 2004Date of Patent: December 26, 2006Assignee: Interhealth Nutraceuticals IncorporatedInventors: Debasis Bagchi, Harry G. Preuss, Shil C. Kothari
-
Patent number: 7119110Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.Type: GrantFiled: October 4, 2002Date of Patent: October 10, 2006Assignee: Interhealth Nutraceuticals IncorporatedInventors: Debasis Bagchi, Harry G. Preuss, Shil C. Kothari
-
Patent number: 7112608Abstract: The present invention relates to novel hydroxyphenylundecane derivatives of the formula (I), a method for the preparation of said compounds by cultivation of the fungus Cryphonectria parasitica, DSM 14453, and their use as pharmaceuticals, i.e. for the treatment of Alzheimer's Disease, Parkinson's Disease, Huntington's Diseases, stroke, psychosis and/or depressions.Type: GrantFiled: October 1, 2003Date of Patent: September 26, 2006Assignee: Sanofi-Aventis Deutschland GmbHInventors: Cordula Hopmann, Martin Knauf, Mark Brönstrup, Astrid Markus-Erb, Luigi Toti
-
Patent number: RE41151Abstract: In accordance with the present invention, there are provided normal modified forms of nonsteroidal anti-inflammatory drugs. Modified NSAIDs according to the invention provide a new class of anti-inflammatory agent which provide the therapeutic benefits of NSAIDs while causing a much lower incidence of side-effects then typically observed with such agents.Type: GrantFiled: August 20, 2008Date of Patent: February 23, 2010Assignee: Medinox, Inc.Inventors: Ching-San Lai, Tingmin Wang